US2016151351A1PendingUtilityA1

Non-abusable pharmaceutical composition comprising opioids

54
Assignee: OREXO ABPriority: Dec 4, 2006Filed: Jun 30, 2015Published: Jun 2, 2016
Est. expiryDec 4, 2026(~0.4 yrs left)· nominal 20-yr term from priority
A61P 25/00A61P 29/00A61P 25/36A61P 25/04A61K 31/485A61K 9/5084A61K 9/1676A61K 9/2077A61K 9/167A61K 9/006A61K 31/4468A61K 9/14
54
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

There is provided pharmaceutical compositions for the treatment of pain comprising a pharmacologically-effective amount of an opioid analgesic, or a pharmaceutically-acceptable salt thereof, presented in particulate form upon the surfaces of carrier particles comprising a pharmacologically-effective amount of an opioid antagonist, or a pharmaceutically-acceptable salt thereof, which carrier particles are larger in size than the particles of the opioid analgesic. The compositions are also useful in prevention of opioid abuse by addicts.

Claims

exact text as granted — not AI-modified
What is claimed is: 
     
         1 . A method of treating a subject in need thereof comprising, administering a particulate transmucosal pharmaceutical composition comprising a pharmacologically-effective amount of an opioid analgesic, or a pharmaceutically-acceptable salt thereof, presented in particulate form upon the surfaces of carrier particles comprising a pharmacologically-effective amount of an opioid antagonist, or a pharmaceutically-acceptable salt thereof, which carrier particles are larger in size than the particles of the opioid analgesic, wherein both of said opioid analgesic and said opioid antagonist are delivered transmucosally, wherein the opioid analgesic is selected from fentanyl, alfentanil, sufentanil, remifentanil and buprenorphine, and the opioid antagonist is selected from nalmefene, methylnaltrexone, naltrexone and naloxone.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.